Pamela McCombe
About
In The Last Decade
Pamela McCombe
223 papers receiving 6.4k citations
Hit Papers
Peers
Comparison fields: 5 of 153
- Neurology 2.8k
- Immunology 1.5k
- Molecular Biology 1.3k
- Genetics 1.1k
- Neurology 964
Countries citing papers authored by Pamela McCombe
This map shows the geographic impact of Pamela McCombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pamela McCombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pamela McCombe more than expected).
Fields of papers citing papers by Pamela McCombe
This network shows the impact of papers produced by Pamela McCombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pamela McCombe. The network helps show where Pamela McCombe may publish in the future.
Co-authorship network of co-authors of Pamela McCombe
This figure shows the co-authorship network connecting the top 25 collaborators of Pamela McCombe. A scholar is included among the top collaborators of Pamela McCombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pamela McCombe. Pamela McCombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 19 | |
| 5 | 22 | |
| 6 | 3 | |
| 7 | 4 | |
| 8 | 10 | |
| 9 | 39 | |
| 10 | 8 | |
| 11 | 27 | |
| 12 | Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up | 2 |
| 13 | Pregnancy Outcomes in Patients with MS Treated with Teriflunomide: Clinical Study and Postmarketing Data | 1 |
| 14 | 38 | |
| 15 | Alemtuzumab demonstrated durable efficacy and safety in CARE-MS I patients switching from SC IFNB-1a: 5-year follow-up after alemtuzumab (TOPAZ study) | 1 |
| 16 | Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study | 2 |
| 17 | Australian cladribine experience | 0 |
| 18 | Alemtuzumab provides durable improvements in clinical outcomes in treatment-naive patients with active relapsing-remitting multiple sclerosis over 6 years in the absence of continuous treatment (CARE-MS I). | 7 |
| 19 | HLA-DR2 is associated with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in females, but not males | 1 |
| 20 | Absence of antimyelin antibodies and serum demyelinating factors in most patients with chronic inflammatory demyelinating polyradiculoneuropathy | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.